The brain penetration of 19 drugs, including P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) substrates, was compared among mice, cynomolgus monkeys and beagle dogs. The brain-to-plasma concentration ratios (K) of the tested compounds in monkey and dog showed good correlation, whereas species differences were observed between non-rodents (monkey/dog) and rodents (mouse). In particular, the K values of 7 compounds out of 12 P-gp substrates (K ratio in P-gp knockout mice versus wild-type mice ≥3) in monkey and dog were more than three-fold higher than those in mice and a similar trend was observed in the brain-to-plasma unbound concentration ratios (K). The cerebral spinal fluid (CSF) drug concentrations (C), a surrogate for unbound brain concentration (C), were also compared between dog and monkey, and the CSF-to-plasma unbound concentration ratios (K) of BCRP substrates in dog were notably higher than those in monkey, although non-bcrp substrates showed good correlation. Also, the K values of BCRP substrates in dog were clearly higher than the K values, indicating that the dog C of BCRP substrates was not suitable as a surrogate of C. These observations should be useful when selecting the appropriate animal models for CNS drug discovery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.dmpk.2021.100426 | DOI Listing |
Drugs R D
December 2024
Galapagos SASU, Romainville, France.
Background And Objective: This study provides a physiologically based pharmacokinetic (PBPK) model-based analysis of the potential drug-drug interaction (DDI) between cyclosporin A (CsA), a breast cancer resistance protein transporter (BCRP) inhibitor, and methotrexate (MTX), a putative BCRP substrate.
Methods: PBPK models for CsA and MTX were built using open-source tools and published data for both model building and for model verification and validation. The MTX and CsA PBPK models were evaluated for their application in simulating BCRP-related DDIs.
Clin Transl Sci
December 2024
Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.
Recent reports suggest that plasma riboflavin may serve as a biomarker for BCRP inhibition in humans. However, the clinical data supporting this claim have been limited, with only two studies showing modest increases in riboflavin levels after administration of a BCRP inhibitor. We have recently demonstrated that co-administration of 375 mg once daily (q.
View Article and Find Full Text PDFJ Chromatogr B Analyt Technol Biomed Life Sci
December 2024
Department of Pharmacy, Hebei General Hospital, Shijiazhuang, China; Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, China. Electronic address:
Pharmaceutics
October 2024
Charles River Laboratories Hungary, H-1117 Budapest, Hungary.
One of the major risks associated with the concomitant use of herbal products and therapeutic drugs is herb-drug interactions (HDIs). The most common mechanism leading to HDIs is the inhibition and/or induction of transport proteins and drug-metabolizing enzymes by herbal ingredients, causing changes in the pharmacokinetic disposition of the victim drug. The present study aimed to determine the potential interactions of (UT) (cat's claw), a popular herb due to its supposed health benefits.
View Article and Find Full Text PDFJ Ethnopharmacol
January 2025
National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, MS, 38677, United States; Department of Bio-Molecular Sciences, School of Pharmacy, The University of Mississippi, MS, 38677, United States. Electronic address:
Ethnopharmacological Relevance: Phyllanthus amarus is ethnomedicinally used to treat gallbladder stones, kidney stones and chronic liver diseases. P. amarus is gaining popularity as an ingredient in many botanical dietary supplements.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!